BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19506455)

  • 1. Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
    Jeremić B; Miličić B
    Am J Clin Oncol; 2009 Oct; 32(5):483-7. PubMed ID: 19506455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
    Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
    J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy.
    Jeremić B; Milicić B
    Radiother Oncol; 2008 May; 87(2):201-3. PubMed ID: 18207598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment prognostic factors of survival in patients with locally advanced nonmetastatic squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
    Jeremić B; Milicić B
    Am J Clin Oncol; 2009 Apr; 32(2):163-8. PubMed ID: 19307954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
    Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K
    Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
    Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
    Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
    Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
    Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL
    Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W; Hehr T; Budach V; Belka C; Dietz K
    BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
    Rades D; Stoehr M; Meyners T; Bohlen G; Nadrowitz R; Dunst J; Schild SE; Wroblewski J; Albers D; Schmidt R; Alberti W; Tribius S
    Strahlenther Onkol; 2008 Apr; 184(4):198-205. PubMed ID: 18398584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.
    Jeremic B; Shibamoto Y; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J; Vaskovic Z; Tadic L
    J Clin Oncol; 2000 Apr; 18(7):1458-64. PubMed ID: 10735893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.